Discover our impact all over the world.

Numbers displayed on the map are a representation of the activity in each country. Once you use the filter selections below, you will have the opportunity to explore projects and faculty in each country.

Projects + Faculty = Activity Number

##

Overview

Projects 304
Countries 145
Faculty 380
Health Topics 123

Filter from the selections below

Clear All Filters

Design and Testing of Novel Vaccines Against Epstein-Barr Virus

Epstein-Barr virus (EBV) is one of the most common human viruses. It is a causative agent of infectious mononucleosis and is associated with ~200 000 new cases of cancer and ~140,000 deaths annually. It is thought that a vaccine that prevents EBV infection and/or associated pathologies would have a significant clinical benefit. However, the kinds of immune responses a protective EBV vaccine would need to elicit have not been defined. Consequently it is not clear which viral antigens are ideal candidates for an EBV vaccine.

To get a better understanding of what types of antibodies a protective EBV vaccine should elicit, we isolate monoclonal antibodies targeting multiple viral proteins from people naturally infected with EBV and evaluate their ability to neutralize, or block infection of multiple cell types, and to block experimental EBV infection in animal models. We couple this with structural information to define critical sites of vulnerability on the virus. We then use this information to design and optimize vaccine antigens that can focus the immune response on key antigenic sites and evaluate their ability to elicit protective antibodies in animal models.